Learning the language of organ rejection may eventually revolutionize organ transplantation.

John Weinberg, MD, COO, Veloxis Pharmaceuticals, describes the benefits of the Veloxis' Envarsus, an orphan drug for the treatment of organ transplant rejection. Envarsus is a reformulation of tacrolimus, the current gold standard of treatment. The new drug breaks down the bonds of the active molecule,...

John Weinberg, MD, COO, Veloxis Pharmaceuticals describes the challenges of organ transplantation. While advancements in the field have minimized the short-term risks of transplantation, the average kidney transplant only lasts about 10-12 years. According to Weinberg, the transience of kidney transplants...